Javascript must be enabled to continue!
Stable expression of promyelocytic leukaemia (PML) protein in telomerase positive MCF7 cells results in alternative lengthening of telomeres phenotype
View through CrossRef
Background
Cancer cells can employ telomerase or the alternative lengthening of telomeres (ALT) pathway for telomere maintenance. Cancer cells that use the ALT pathway exhibit distinct phenotypes such as heterogeneous telomeres and specialised Promyelocytic leukaemia (PML) nuclear foci called APBs. In our study, we used wild-type PML and a PML mutant, in which the coiled-coil domain is deleted (PML C/C-), to investigate how these proteins can affect telomere maintenance pathways in cancer cells that use either the telomerase or ALT pathway.
Results
Stable over-expression of both types of PML does not affect the telomere maintenance in the ALT cells. We report novel observations in PML over-expressed telomerase-positive MCF7 cells: 1) APBs are detected in telomerase-positive MCF7 cells following over-expression of wild-type PML and 2) rapid telomere elongation is observed in MCF7 cells that stably express either wild-type PML or PML C/C-. We also show that the telomerase activity in MCF7 cells can be affected depending on the type of PML protein over-expressed.
Conclusion
Our data suggests that APBs might not be essential for the ALT pathway as MCF7 cells that do not contain APBs exhibit long telomeres. We propose that wild-type PML can either definitively dominate over telomerase or enhance the activity of telomerase, and PML C/C- can allow for the co-existence of both telomerase and ALT pathways. Our findings add another dimension in the study of telomere maintenance as the expression of PML alone (wild-type or otherwise) is able to change the dynamics of the telomerase pathway.
Title: Stable expression of promyelocytic leukaemia (PML) protein in telomerase positive MCF7 cells results in alternative lengthening of telomeres phenotype
Description:
Background
Cancer cells can employ telomerase or the alternative lengthening of telomeres (ALT) pathway for telomere maintenance.
Cancer cells that use the ALT pathway exhibit distinct phenotypes such as heterogeneous telomeres and specialised Promyelocytic leukaemia (PML) nuclear foci called APBs.
In our study, we used wild-type PML and a PML mutant, in which the coiled-coil domain is deleted (PML C/C-), to investigate how these proteins can affect telomere maintenance pathways in cancer cells that use either the telomerase or ALT pathway.
Results
Stable over-expression of both types of PML does not affect the telomere maintenance in the ALT cells.
We report novel observations in PML over-expressed telomerase-positive MCF7 cells: 1) APBs are detected in telomerase-positive MCF7 cells following over-expression of wild-type PML and 2) rapid telomere elongation is observed in MCF7 cells that stably express either wild-type PML or PML C/C-.
We also show that the telomerase activity in MCF7 cells can be affected depending on the type of PML protein over-expressed.
Conclusion
Our data suggests that APBs might not be essential for the ALT pathway as MCF7 cells that do not contain APBs exhibit long telomeres.
We propose that wild-type PML can either definitively dominate over telomerase or enhance the activity of telomerase, and PML C/C- can allow for the co-existence of both telomerase and ALT pathways.
Our findings add another dimension in the study of telomere maintenance as the expression of PML alone (wild-type or otherwise) is able to change the dynamics of the telomerase pathway.
Related Results
Data from Characterization of Endogenous Human Promyelocytic Leukemia Isoforms
Data from Characterization of Endogenous Human Promyelocytic Leukemia Isoforms
<div>Abstract<p>Promyelocytic leukemia (<i>PML</i>) has been implicated in a variety of functions, including control of TP53 function and modulation of cell...
Data from Characterization of Endogenous Human Promyelocytic Leukemia Isoforms
Data from Characterization of Endogenous Human Promyelocytic Leukemia Isoforms
<div>Abstract<p>Promyelocytic leukemia (<i>PML</i>) has been implicated in a variety of functions, including control of TP53 function and modulation of cell...
Rôle différentiel des isoformes de PML en réponse au trioxyde d’arsenic et dans la défense antivirale
Rôle différentiel des isoformes de PML en réponse au trioxyde d’arsenic et dans la défense antivirale
Les interférons (IFN) constituent une famille de cytokines aux propriétés antiprolifératives et antivirales. Ils activent, via la voie Jak/STAT, des gènes spécifiques dont les prod...
Treating Cancer by Targeting Telomeres and Telomerase
Treating Cancer by Targeting Telomeres and Telomerase
Telomerase is expressed in more than 85% of cancer cells. Tumor cells with metastatic potential may have a high telomerase activity, allowing cells to escape from the inhibition of...
7
th
International Symposium on Enabling Technologies for Life Sciences (ETP)
7
th
International Symposium on Enabling Technologies for Life Sciences (ETP)
The seventh in the series of ETP Symposia (see
Rapid Communications in Mass Spectrometry
2012,
26
, ...
Promyelocytic leukemia nuclear body-like structures can assemble in mouse oocytes
Promyelocytic leukemia nuclear body-like structures can assemble in mouse oocytes
ABSTRACT
Promyelocytic leukemia (PML) nuclear bodies (PML-NBs), a class of membrane-less cellular organelles, participate in various biological activities. PML-NBs a...
Characterization of telomeric defects and signal transduction pathways in Dyskeratosis Congenita cells
Characterization of telomeric defects and signal transduction pathways in Dyskeratosis Congenita cells
<p>Telomere attrition is a natural process that occurs due to inadequate telomere maintenance. Once at a critically short threshold, telomeres signal the cell to cease divisi...
The PML gene is not involved in the regulation of MHC class I expression in human cell lines
The PML gene is not involved in the regulation of MHC class I expression in human cell lines
The promyelocytic leukemia gene, PML, is a growth and transformation suppressor. An additional role forPML as a regulator of major histocompatibility complex (MHC) class I antigen ...

